Navigation Links
Dey, L.P. Settles State of Alabama Pricing Litigation
Date:1/9/2008

NAPA, Calif., Jan. 9 /PRNewswire/ -- Dey, L.P. today announced that it has settled a lawsuit brought against it and other companies by the State of Alabama in January 2005 pertaining to Medicaid reimbursements paid by the state to pharmacists and other healthcare providers. In exchange for a full release of claims, Dey has agreed to pay the state $4.75 million, $750,000 of which accounts for outside legal fees and expenses.

As part of the acquisition agreement between Mylan Inc. (Dey's parent company) and Merck KGaA (Dey's former parent company), Merck has agreed to indemnify Mylan in connection with this settlement and for all liability for all pending and future related Medicaid reimbursement lawsuits involving Dey.

As part of the settlement, the state acknowledges that the settlement does not constitute admission or evidence of fault, liability or unlawful conduct by Dey.

About Dey, L.P.

Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey, L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey, L.P. include http://www.dey.com, http://www.accuneb.com, http://www.curosurfusa.com, http://www.cyanokit.com, http://www.duoneb.com, http://www.epipen.com and http://www.perforomist.com.

About Mylan Inc.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

Media Contacts: Dey, L.P. Media Line

800-755-5560 x8363

or

Harriet Ullman

Feinstein Kean Healthcare

617-761-6776

hullman@fkhealth.com


'/>"/>
SOURCE Dey, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Park Dental Doctor Group Settles Litigation With Service Provider
2. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
3. Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter
4. Sunrise Settles Litigation Regarding Its 2007 Annual Meeting
5. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
6. Global Med Technologies(R) Adds Eighth SafeTrace Tx(R) Client in New York State
7. Fatherhood Tied to Higher Prostate Cancer Risk
8. Fatherhood linked to prostate cancer risk
9. Michigan Quality Council (MQC) Names Oakwood Healthcare Inc. 2007 State Quality Award Recipient
10. RxElite Registration Statement Suspended
11. Susan G. Komen for the Cure, Ryan Community Health Centers, Breast Cancer Survivors Call on New York State to Expand Breast Cancer Screening, Treatment Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology: